Coherus Oncology (CHRS) Total Liabilities (2013 - 2026)
Coherus Oncology (CHRS) posted Total Liabilities of $187.4 million for Q1 2026, down 5.03% sequentially from $197.3 million in Q4 2025, and down 66.21% YoY from $554.5 million in Q1 2025.
Coherus Oncology (CHRS) Total Liabilities (2013 - 2026) Analysis & Trends
Coherus Oncology has reported Total Liabilities for 14 years, with the latest figure at $187.4 million in Q1 2026.
- Quarterly Total Liabilities fell 66.21% year-over-year to $187.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $187.4 million (down 66.21% YoY) and the FY2025 annual result came in at $197.3 million, down 66.01% from the prior year.
- Total Liabilities eased to $187.4 million in Q1 2026 per CHRS's latest filing, from $197.3 million in the prior quarter.
- Over five years, Total Liabilities peaked at $845.4 million in Q1 2024 and troughed at $187.4 million in Q1 2026.
- A 5-year average of $568.5 million and a median of $593.0 million in 2024 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2024 and 2026: Total Liabilities soared 41.15% in 2024, then slumped 66.21% in 2026.
- Over 5 years, Total Liabilities stood at $618.3 million in 2022, then jumped by 33.12% to $823.0 million in 2023, then decreased by 29.47% to $580.5 million in 2024, then tumbled by 66.01% to $197.3 million in 2025, then retreated by 5.03% to $187.4 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $187.4 million, $197.3 million, and $428.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.92 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.57 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 59.12 Bn | 53.98 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.75 Bn | 28.45 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.72 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.20 Bn | 26.36 Bn | - | 10.03 Bn |
| 10 | Coherus Oncology | 212.28 Mn | 106.98 Mn | 10.07 Mn | 130.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 130.35 Mn |
| Mar 31, 2026 | 187.40 Mn |
| Dec 31, 2025 | 197.33 Mn |
| Sep 30, 2025 | 428.75 Mn |
| Jun 30, 2025 | 319.64 Mn |
| Mar 31, 2025 | 554.54 Mn |
| Dec 31, 2024 | 580.52 Mn |
| Sep 30, 2024 | 592.97 Mn |
| Jun 30, 2024 | 758.96 Mn |
| Mar 31, 2024 | 845.39 Mn |
| Dec 31, 2023 | 823.03 Mn |
| Sep 30, 2023 | 717.38 Mn |
| Jun 30, 2023 | 644.36 Mn |
| Mar 31, 2023 | 598.93 Mn |
| Dec 31, 2022 | 618.27 Mn |
| Sep 30, 2022 | 648.04 Mn |
| Jun 30, 2022 | 568.63 Mn |
| Mar 31, 2022 | 580.82 Mn |
| Dec 31, 2021 | 581.61 Mn |
| Sep 30, 2021 | 610.97 Mn |